Table 2 Cox proportional hazard analysis (95% CI) for persistence of TNF inhibitor
HRnaive(n = 1,468) | HRcontinuing(n = 733) | HRoverall(n = 2,201) | |
|---|---|---|---|
Gender (0: male/1: female) | 0.942 (0.780-1.138) | 0.937 (0.723-1.215) | 0.943 (0.810-1.099) |
Age | 0.999 (0.994-1.005) | 0.990 (0.983-0.997)* | 0.996 (0.992-1.000) |
Medication (reference category: Infliximab) | |||
Etanercept | 0.960 (0.788-1.170) | 1.084 (0.850-1.381) | 1.001 (0.865-1.175) |
Adalimumab | 0.956 (0.786-1.163) | 1.023 (0.790-1.323) | 0.983 (0.842-1.148) |
Charlson Comorbidities Index | 1.018 (0.968-1.071) | 1.055 (0.974-1.143) | 1.030 (0.987-1.075) |
Naive | - | - | 1.296 (1.164-1.443)** |